Search
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalBelatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Struct...
Ulobetasol
go.drugbank.com/drugs/DB00596ApprovedUlobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. Ulobetasol was...
Flutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalFlutemetamol (18F), an analogue of [(11)C]PIB, is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density. It is used to evaluate Alzheimer's disease (A...
Snubh-nm-333 F-18
go.drugbank.com/drugs/DB15457ExperimentalSnubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)).
Synonyms: SNUBH-NM-333(18F)Atidarsagene autotemcel
go.drugbank.com/drugs/DB17538ApprovedInvestigational[L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic
NP-G2-044
go.drugbank.com/drugs/DB14995InvestigationalNP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Clesrovimab
go.drugbank.com/drugs/DB18877Approved[L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigationaldurvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no